[CLAIMS]

[Claim 1]
Use of 5-fluoro-2-[(4-{7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl}pyrimidin-5-yl)oxy]-N,N-di(propan-2-yl)benzamide (hereinafter, it may be referred to as "free form") or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof as an active ingredient in the manufacture of a medicament, for treating or preventing a cancer, wherein the medicament is to be orally administered to a subject in need thereof.

[Claim 2]
The use of claim 1, wherein the medicament is to be orally administered to a subject in need thereof once a day.

[Claim 3]
The use of claim 1, wherein the medicament is to be orally administered to a subject in need thereof twice a day.

[Claim 4]
The use of any one of claims 1 to 3, wherein one dose of the active ingredient is 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 140 mg, 180 mg, 200 mg, 220 mg, 240 mg, 260 mg, 280 mg, 300 mg, 320 mg, 340 mg, 360 mg, 380 mg, 400 mg, 500 mg, or 600 mg converted to the free form.

[Claim 5]
The use of any one of claims 1 to 4, wherein the medicament is to be used in combination with a different drug or a pharmaceutically acceptable salt thereof, wherein the different drug is at least one drug selected from an antitumor alkylating agent, an antitumor antimetabolite, an antitumor antibiotic, a plant-derived antitumor medicament, an antitumor platinum complex compound, an antitumor camptothecin derivative, an antitumor tyrosine kinase inhibitor, an antitumor serine/threonine kinase inhibitor, an antitumor phospholipid kinase inhibitor, an antitumor monoclonal antibody, interferon, a biological response modifier, a hormone preparation, an angiogenic inhibitor, an immune checkpoint inhibitor, an epigenetics-associated molecular inhibitor, a protein post-translational modification inhibitor, a proteasome inhibitor, and other antitumor medicaments.

[Claim 6]
The use of any one of claims 1 to 4, wherein the medicament is to be used in combination with a different drug or a pharmaceutically acceptable salt thereof, wherein the different drug is at least one drug selected from
(1) venetoclax and azacitidine
(2) cytarabine and daunorubicin, and
(3) gilteritinib.

[Claim 7]
The use of any one of claims 1 to 4, wherein the medicament is to be administered in combination with gilteritinib once a day.

[Claim 8]
The use of any one of claims 1 to 4, wherein the medicament is to be administered in combination with 120 mg of gilteritinib.

[Claim 9]
The use of any one of claims 1 to 8, wherein the cancer is leukemia, polycythemia vera, malignant lymphoma, B-cell lymphoma, myeloma, brain tumor, cancer of the head and neck, esophageal cancer,

thyroid cancer, small cell lung cancer, non-small cell lung cancer, breast cancer, gastric cancer, gallbladder and bile duct cancer, liver cancer, hepatocellular cancer, pancreatic cancer, colon cancer, rectal cancer, anal cancer, chorionepithelioma, endometrial cancer, cervical cancer, ovarian cancer, bladder cancer, urothelial cancer, renal cancer, renal cell cancer, prostate cancer, testicular tumor, testicular germ cell tumor, ovarian germ cell tumor, Wilms' tumor, malignant melanoma, neuroblastoma, osteosarcoma, Ewing's sarcoma, chondrosarcoma, soft tissue sarcoma, or skin cancer.

[Claim 10]
The use of any one of claims 1 to 8, wherein the cancer is leukemia, B-cell lymphoma, neuroblastoma, or prostate cancer.

[Claim 11]
The use of any one of claims 1 to 8, wherein the cancer is leukemia.

[Claim 12]
The use of any one of claims 9 to 11, wherein the leukemia is acute leukemia, chronic lymphocytic leukemia, or chronic myeloid leukemia.

[Claim 13]
The use of claim 12, wherein the acute leukemia is MLL acute leukemia, MLL partial tandem duplicate acute leukemia, or NPM1 mutated acute leukemia.

[Claim 14]
The use of claim 12, wherein the acute leukemia is MLL acute leukemia or NPM1 mutated acute leukemia.

[Claim 15]
The use of claim 12, wherein the acute leukemia is acute myeloid leukemia with MLL rearrangement.

[Claim 16]
The use of claim 12, wherein the acute leukemia is relapsed or refractory acute myeloid leukemia with MLL rearrangement.

[Claim 17]
The use of claim 12, wherein the acute leukemia is acute lymphoid leukemia with MLL rearrangement.

[Claim 18]
The use of claim 12, wherein the acute leukemia is relapsed or refractory acute lymphoid leukemia with MLL rearrangement.

[Claim 19]
The use of claim 12, wherein the acute leukemia is acute myeloid leukemia with NPM1 mutation.

[Claim 20]
The use of claim 12, wherein the acute leukemia is relapsed or refractory acute myeloid leukemia with NPM1 mutation.

[Claim 21]
The use of claim 12, wherein the acute leukemia is leukemia accompanied by high expression of HOXa gene cluster or MEIS gene cluster.

[Claim 22]

The medicament of any one of claims 1 to 8, wherein the cancer is tumor accompanied by p53 gain-of-function mutation.

[Claim 23]
The use of any one of claims 1 to 8, wherein the cancer exhibits at least one genetic abnormality selected from NPM1 gene mutation, DNMT3A gene mutation, FLT gene mutation, and MLL translocation.

[Claim 24]
The use of any one of claims 1 to 8, wherein the cancer exhibits at least one genetic abnormality selected from NPM1 gene mutation, FLT gene mutation, and MLL translocation.

[Claim 25]
The use of any one of claims 1 to 8, wherein the cancer exhibits at least one genetic abnormality selected from NPM1 gene mutation and MLL translocation.

[Claim 26]
The use of any one of claims 1 to 25, wherein the medicament is to be administered to a subject having at least one genetic abnormality selected from NPM1 gene mutation, DNMT3A gene mutation, FLT gene mutation, and MLL translocation.

[Claim 27]
The use of any one of claims 1 to 25, wherein the medicament is to be administered to a subject having at least one genetic abnormality selected from NPM1 gene mutation and MLL translocation.

[Claim 28]
The use of any one of claims 1 to 25, wherein the medicament is to be administered to a subject having NPM1 gene mutation.

[Claim 29]
The use of claim 28, wherein the subject having NPM1 gene mutation is determined based on
(1) the detection of the NPM1 gene mutation in cancer cells obtained from the subject, and
(2) the determination of presence/absence of the NPM1 gene mutation detected in (1).

[Claim 30]
The use of any one of claims 1 to 25, wherein the medicament is to be administered to a subject having MLL translocation.

[Claim 31]
The use of claim 30, wherein the subject having MLL translocation is determined based on
(1) the detection of the MLL translocation in cancer cells obtained from the subject, and
(2) the determination of presence/absence of the MLL translocation detected in (1).

[Claim 32]
The use of any one of claims 1 to 25, wherein the medicament is to be administered to a subject having FLT gene mutation.

[Claim 33]
The use of claim 32, wherein the subject having FLT gene mutation is determined based on
(1) the detection of the FLT gene mutation in cancer cells obtained from the subject, and
(2) the determination of presence/absence of the FLT gene mutation detected in (1).

[Claim 34]
The use of any one of claims 1 to 25, wherein the medicament is to be administered to a subject having DNMT3A gene mutation.

[Claim 35]
The use of claim 34, wherein the subject having DNMT3A gene mutation is determined based on
(1) the detection of the DNMT3A gene mutation in cancer cells obtained from the subject, and
(2) the determination of presence/absence of the DNMT3A gene mutation detected in (1).